Diabetes and Metabolism Journal

Korean Diabetes Association (대한당뇨병학회)
권호 표지

The Effects of D-Chiro-Inositol on Glucose Metabolism in 3T3-L1 Cells

3T3-L1세포에서의 포도당 대사에 대한 D-Chiro-Inositol의 영향

Park, Kang-Seo;Lee, Jae-Min;Ku, Bon-Jeong;Jo, Young-Suk;Lee, Seong-Kyu;Min, Kyung-Wan;Han, Kyung-Ah;Kim, Hyo-Jeong;Kim, Hyun-Jin
박강서;이재민;구본정;조영석;이성규;민경완;한경아;김효정;김현진

  • Published : 2008.06.01
⟨ Previous Next ⟩

Abstract

Background: The target of the treatment of metabolic syndrome and diabetes is an improvement of insulin resistance. D-chiro-inositol(DCI) plays a role in a phospholipid mediating intracellular insulin action. In the previous studies, the urine level of DCI were decreased in the diabetic animal with insulin resistance. Some clinical studies showed that DCI improved a glucose level and HbA1c. Therefore we studied the relationship between DCI and glucose metabolism, especially insulin resistance.Methods: To investigate the mechanism of DCI affecting the glucose metabolism, we examined the effects of DCI on 2-deoxyglucose uptake, gene expression of adipocytokines and AMPK pathway by using RT-PCR and western blot in 3T3-L1 cells. Results: Insulin-stimulated 2-deoxyglucose uptake increased in DCI-treated cells by about 1.2-fold(relative to the control) and was inhibited by phosphoinositide 3-kinase(PI3 Kinase) inhibitors(Wortmanin, LY294002) and AMPK inhibitor(STO-609). In Western blot analysis, it didn't show the difference of phosphorylation of Akt and AMPK between DCI-treated group and control in 3T3-L1 cells. However, DCI decreased the gene expression of resistin in 3T3-L1 cells. Conclusion: DCI may involve other pathway of insulin signaling, but not PI3 Kinase and AMPK signaling pathways and it may be useful in managing metabolic syndrome by improving insulin resistance through increasing glucose uptake and decreasing resistin relevant to insulin resistance.(KOREAN DIABETES J 32:196-203, 2008)

연구배경: D-Chiro-Inositol(DCI)은 인슐린 작용을 매개하는 인지질이다. 이전 연구에서 인슐린저항성을 나타내는 당뇨병환자나 동물 모델에서의 소변 배출이 감소하는 것이 보고되었다. 따라서, 저자들은 DCI가 포도당 대사 및 이와 관련된 인자들에 미치는 영향을 알아보고, 아디포사이토카인과의 연관성을 알아보기 위해 본 연구를 수행하였다. 연구방법: 3T3-L1 세포에서 2-deoxyglucose를 이용하여 DCI에 의한 포도당 이용률을 측정하고, DCI의 작용 경로를 확인하기 위해 western blot을 시행하였다. 또한 당대사와 관련된 아디포사이토카인과의 연관성을 위해 real-time PCR을 수행하였다. 결과: 3T3-L1 세포에서 포도당 이용률은 대조군에 비해 약 1.2배 정도 증가하였으며, 이는 PI3K 억제제와 AMPK 억제제 투여 시 감소하였다. Western blot상 DCI는 Akt와 AMPK의 인산화는 대조군과 차이를 보이지 않았다. 그리고, 레지스틴의 유전자 발현은 상대적으로 감소하였다.

Keywords

References

  1. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-607, 1988 https://doi.org/10.2337/diabetes.37.12.1595
  2. 장학철, 임수, 조남한: 대사증후군의 현황. 대한내과학회지 67:528-32, 2004
  3. Krentz AJ: Insulin resistance. BMJ 313:1385-9, 1996 https://doi.org/10.1136/bmj.313.7069.1385
  4. Cefalu WT: Insulin resistance: cellular and clinical concepts. Exp Biol Med 226:13-26, 2001 https://doi.org/10.1177/153537020122600103
  5. Mlinar B, Marc J, Janez A, Pfeifer M: Molecular mechanisms of insulin resistance and associated diseases. Clinica Chimica Acta 375:20-35, 2007 https://doi.org/10.1016/j.cca.2006.07.005
  6. Moller DE, Bjorbaek C, Vidal-Puig A: Candidate genes for insulin resistance. Diabetes care 19:396-400, 1996 https://doi.org/10.2337/diacare.19.4.396
  7. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473-86, 1995 https://doi.org/10.1152/physrev.1995.75.3.473
  8. DeFronzo RA, Bonnadonna RC, Ferrannini E: Pathogenesis of NIDDM. A ballanced overview. Diabetes Care 15:318-68, 1992 https://doi.org/10.2337/diacare.15.3.318
  9. Ferrannini E, Buzziogoli G, Bonadinna R: Insulin resistance in essential hypertension. N Engl J Med 317:350-7, 1987 https://doi.org/10.1056/NEJM198708063170605
  10. Shamiss A, Carroll J, Rosenthal T: Insulin reistance in secondary hypertension. Am J Hypertens. 5:26-8, 1992 https://doi.org/10.1093/ajh/5.1.26
  11. Polonsky KS, Sturis J, Bell GI: Seminars in Medicine of Beth Israel Hospital, Boston. Non-insulin-depenedent diabetes mellitus - genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 334:777-83, 1996 https://doi.org/10.1056/NEJM199603213341207
  12. Bailey CJ, Turner RC: Metformin N Engl J Med 334:574-9, 1996 https://doi.org/10.1056/NEJM199602293340906
  13. Olefsky JM: Treatment of insulin resistance with peroxisome proliferator- activated receptor gamma agonist. J Clin Invest 106:462-72, 2000
  14. Jones DR, Varela-Nieto I: The role of glycosyl-phophatidylinositol in signal transduction. Int J Biochem Cell Biol. 30:313-26, 1998 https://doi.org/10.1016/S1357-2725(97)00144-1
  15. Alan RS, Marvin IS, Steven J, Pedero C: Putative mediators of insulin action: Regulation of pyruvate dehydrogenase and adenylate cyclase activities. Proc Natl Acd Sci USA 79:3513-7, 1982
  16. Ortmeyer HK, Bodkin NL, Hansen BC, Larner J: In vivo D-chiro-inositol activates skeletal muscle glycogen synthase and inactivates glycogen phosphorylase in rhesus monkeys. J Nutr Biochem 6:499-503, 1995 https://doi.org/10.1016/0955-2863(95)00080-J
  17. Galasko GT, Abes S, Lilley K, Zhang C, Larner J: Circulating factors and insulin resistance.II The action of the novel myo-inositol cyclic 1,2-inositol phosphate phosphoglycan insulin antagonist from human in regulating pyruvate dehydrogenase phosphatase. J Clin Endocrinol Metab. 81:1051-7, 1996 https://doi.org/10.1210/jc.81.3.1051
  18. Daughaday WH, Larner J: The renal excretion of inositol in normal and diabetic human being. J Clin Invest 33:326-32, 1954 https://doi.org/10.1172/JCI102901
  19. Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J: Both myo-inositol to chiro-inositol epimerase activates and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared Wistar controls. Biochem Biophys Biophys Commun. 293:1092-8, 2002 https://doi.org/10.1016/S0006-291X(02)00313-3
  20. Kennigton AS, Hill CR, Craig J, Bogardus CR, Raz I, Ortmeyer HK: Low urinary chiro-inositol excretion in noninsulin-dependent diabetes mellitus. N Engl J Med 323:373-8, 1990 https://doi.org/10.1056/NEJM199008093230603
  21. Bates SH, Jones RB, Bailey CJ: Insulin-like effect of pinitol. Br J Pharmacol 130:1944-8, 2000 https://doi.org/10.1038/sj.bjp.0703523
  22. Ostlund RE JR, McGill JB, Herskowitz I, Kipnis DM, Santiago JV: D-Chiro-Inositol metabolism in diabetes mellitus. Proc Natl Acad Sci USA 90:9988-92, 1993
  23. Shashkin PN, Shashkina EF, Fernqvist-Forbes E, Zhou YP, Grill V: Insulin mediators in man: effects of glucose ingestion and insulin resistance. Diabetologia 40:557-63, 1997 https://doi.org/10.1007/s001250050715
  24. Larner J, Allan G, Kessier C, Reamer P, Gunn R, Huang LC: Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. J Basic Clin Physiol Pharmacol 9:127-37, 1998
  25. Asplin I, Galasko G, Larner J: chiro-inositol deficiency and insulin resistance: A comparison of the chiro-inositol- and the myo-inositol-containg insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 90: 5924-8, 1993
  26. Orlicky DJ, Lieber JG, Morin CL, Evans RM: Synthesis and accumulation of a receptor regulatory protein associated with lipid droplet accumulation in 3T3-L1 cells. J Lipid Res 39:1152-61, 1998
  27. Nia JB, Roland G, David EJ: Regulated transport of the glucose transporter GLUT4 Nature molecular biology 3:267-77, 2002 https://doi.org/10.1038/nrm782
  28. Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806, 2001 https://doi.org/10.1038/414799a
  29. Kido Y, Nakae J, Accili D: The Insulin Receptor and Its Cellular Targets. J Clin Enodocrinol Metab 86:972-9, 2001 https://doi.org/10.1210/jc.86.3.972
  30. Robert VF: Insulin-Sensitive Phospholipid Signaling System and Glucose Transport. Update II. Exp Biol Med Vol. 226:283-95, 2001 https://doi.org/10.1177/153537020122600404
  31. Chen H: Cellular inflammatory response: Novel insights for obesity and insulin resistance. Pharmacol Res 53: 469-77, 2006 https://doi.org/10.1016/j.phrs.2006.03.003
  32. Zhao YF, Feng DD, Chen C: Contribution of adipocyte-derived factors to beta-cell dysfunction in diabetes. Int J Biochem Cell Biol 38:804-19, 2006 https://doi.org/10.1016/j.biocel.2005.11.008
  33. Ryu ST, Park SO, Kim SH: The Relation of Serum Adiponectin and Resistin Concentrations with Metabolic Risk Factors. J Kor Soc Endocrinol 20:444-51, 2005 https://doi.org/10.3803/jkes.2005.20.5.444
  34. Davis A, Christinansen M, Horoxitz JF, Klein S, Hellerstein MK: Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care 23:1000-5, 2000 https://doi.org/10.2337/diacare.23.7.1000
  35. Kim JI, Kim JC, Kang MJ, Lee MS, Kim JJ: Effects of pinitol isolated from soybeans on glycemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. Eur J Clin Nutr 59:456-8, 2005 https://doi.org/10.1038/sj.ejcn.1602081
  36. Kang MJ, Kim JI, Yoon SY, Kim JC, Cha IJ: Pinitol from soybeans postprandial blood glucose in patients with type 2 diabetes mellitus. J Med Food 9:182-6, 2006 https://doi.org/10.1089/jmf.2006.9.182
  37. 구본정, 김현진, 박강서: 제2형 당뇨병환자에서 D-chiro-inositol의 혈당강하 효과. 대한내과학회지 72:29-36, 2007
  38. Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell metab 1:15-25, 2005 https://doi.org/10.1016/j.cmet.2004.12.003
  39. Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol 64:335-65, 2006
  40. Widajaja A, Stratton IM, Horn M, Holman RR, Turner R: Plasma leptin, obesity, and plasma insulin in type 2 diabetics. J Clin Endocrinol Metab 82:654-7, 1997 https://doi.org/10.1210/jc.82.2.654
  41. Tanizawa Y, Okuya S, Ishihara H, Asano T, Yada T: Direct stimulation of basal insulin secretion from isolated rat pancreatic beta cells. Endocrinology 138:4513-6, 1997 https://doi.org/10.1210/en.138.10.4513
  42. McTernan CL, McTernan PG, Harte AL, Levick PI, Barnett AH: Resistin, central obesity, and type 2 diabetes. Lancet 359:46-7, 2002 https://doi.org/10.1016/S0140-6736(02)07281-1
  43. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR: The hormone resistin link obesity to diabetes. Nature 259:46-7, 2001
  44. Rajala MW, Obici S, Scherer PE, Rossetti L: Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225-30, 2003 https://doi.org/10.1172/JCI16521